BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

ProPhase Labs, Inc. (Formerly Known as Quigley Corporation) (QGLY) Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2011


3/6/2012 9:31:49 AM

DOYLESTOWN, PA--(Marketwire - March 06, 2012) -

ProPhase Labs (NASDAQ: PRPH) www.ProPhaseLabs.com today reported net sales of $7.5 million for the three months ended December 31, 2011, compared to net sales of $6.2 million for the three months ended December 31, 2010.

The Company incurred a net loss for the three months ended December 31, 2011, of $1.8 million, or ($0.12) per share, compared to a net loss of $1.1 million, or ($0.08) per share, for the three months ended December 31, 2010.

Results for the fourth quarter of 2011 compared to the fourth quarter of 2010 principally reflect the net effect of (i) an increase in net sales of $1.3 million, offset by (ii) an increase in sales and marketing expense of $1.4 million and (iii) an increase in research and development costs of $410,000.

Net sales increased $3.0 million, or 20.3%, to $17.5 million for the year ended December 31, 2011 as compared to $14.5 million for the year ended December 31, 2010. The increase in net sales is principally due to (i) an increase in our retail customers' purchases in the first and fourth quarter of fiscal 2011, as compared to the comparable fiscal 2010 periods, in an effort by those retailers to maintain adequate shelf and warehouse stock during peak seasonal demand to meet an increase in consumer demand at retail of the Company's over-the-counter ("OTC") cold remedy products, (ii) sales of our Cold-EEZE® Oral Spray, a new product launched in August 2011 and (iii) an increase associated with the Company's retail customers increasing the number, timing and value of our promotional and/or display programs as a consequence of, among other influences, (a) space availability, (b) allocation of more promotional space to the Cold-EEZE® brand and (c) a general increase in off-shelf, price promotion opportunities scheduled for the 2011-2012 Cold Season.

In addition to the increase in net sales for the year ended December 31, 2011 as compared to the year ended December 31, 2010, the Company strategically increased its investment in sales and marketing initiatives. For the year ended December 31, 2011, sales and marketing expense increased $2.3 million to $7.9 million as compared to $5.6 million for the year ended December 31, 2010. The Company expects to continue to increase marketing and advertising expenditures in the future, in an effort to build and grow the sales of its OTC cold remedy products.

The Company incurred a net loss for the year ended December 31, 2011, of $2.7 million, or ($0.18) per share, compared to a net loss of $3.5 million, or ($0.25) per share, for the year ended December 31, 2010.

Results for the three months and the year ended December 31, 2011 as compared to the three months and the year ended December 31, 2010 reflect positive trends regarding net sales and improved margins during the respective 2011 periods as compared to the 2010 periods. The Company's strategic focus continues to be (i) revenue growth, (ii) strategic marketing expenditures to communicate the Cold-EEZE® message to consumers, (iii) product development and cost effective commercialization of new products, and (iv) effective cost management pertaining to overhead and general operating costs.

Ted Karkus, ProPhase Labs' Chairman and CEO, stated, "Our goal for the year ended December 31, 2011 was to grow our net sales and to reestablish our Cold-EEZE® brand as a leading cold remedy. Given the difficult environment in the cough/cold category (due to the lower incidence of upper respiratory illness versus the prior year), we are particularly pleased with having achieved these goals."

Mr. Karkus continued, "Fiscal 2010 was a transformation year in which we implemented a number of initiatives including improvements in product packaging and flavors, brand positioning and new product development. In fiscal 2011, we leveraged these initiatives with a carefully developed, fully integrated marketing campaign that included national TV and Radio, PR, Social Media, Digital, national sampling, trade advertising as well as significant in-store merchandising programs. In each channel or medium, every message was carefully crafted to achieve maximum effectiveness. Furthermore, every dollar was spent to achieve maximum reach and frequency of our brand message to our target audience. This combination of an efficient spend and effective message drove positive sales growth in our flagship Cold-EEZE brand during a period in which the incidence of upper respiratory illness was down year over year and in which retail sales for many cough/cold brands were down as well."

Mr. Karkus added, "Our success in building revenues in fiscal 2011 demonstrates that we now have a stronger distribution platform to launch new products and applications. In August 2011 we launched Cold-EEZE® Oral Spray which provides the same active ingredients for shortening the duration of the common cold as our clinically proven Cold-EEZE® lozenges, but in a new and convenient delivery system. This introduction was a natural next step in our evolution as a Company and at the core of our strategy to provide additional cold relief products for our loyal consumers that leverages our flagship Cold-EEZE® brand and adds incremental revenues for our Company. Initial retail and consumer response to our Cold-EEZE® Oral Spray is encouraging. We also hope to launch an additional Cold-EEZE® branded cold remedy product in the third quarter of fiscal 2012."

Mr. Karkus also noted, "For the year ended December 31, 2011, our net sales increased over 20%. Given the infrastructure required to maintain our distribution platform and business operations, we will need to increase our revenues further while maintaining reasonable margins if we are to achieve positive cash flow and profitability on an annualized basis down the road. In addition to introducing new products, efficiently increasing sales and marketing expenses will be the best strategy to achieve this revenue growth goal. Obviously, increasing these expenses will continue to impact near term profitability. We are also making important investments with a long term outlook to establish a development pipeline of new OTC products, including formulations developed by our Phusion joint venture. Our joint venture licenses a revolutionary proprietary technology that has the potential to improve the delivery and/or efficacy of OTC active ingredients and compounds."

Mr. Karkus concluded, "Given the expense and the historic lack of investor participation, we are suspending quarterly investor conference calls until we determine that sufficient interest develops. Furthermore, we will be hosting our Annual Meeting of Shareholders in April, during which management will provide an overview of our Company."

About ProPhase Labs

ProPhase Labs is a diversified natural health medical science company. It is a leading marketer of the Cold-EEZE® cold remedy brand as well as other cold relief products. Cold-EEZE® zinc gluconate lozenges are clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE® customers include leading national retailers, chain food, drug and mass merchandise stores, wholesalers and distributors, as well as independent pharmacies. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE® lozenges and fulfill other contract manufacturing opportunities. ProPhase also owns 50% of Phusion Laboratories, LLC ("Phusion"). Phusion licenses a revolutionary proprietary technology that has the potential to improve the delivery and/or efficacy of many active ingredients or compounds. Phusion will formulate and test products to exploit market opportunities within ProPhase's robust over-the-counter distribution channels. For more information visit us at www.ProPhaseLabs.com.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions; government regulations; the ability of our new management to successfully implement our business plan and strategy; our ability to fund our operations including the cost and availability of capital and credit; our ability to compete effectively including our ability to maintain and increase our market share in the markets in which we do business; and our dependence on sales from our main product, Cold-EEZE®, and our ability to successfully develop and commercialize new products.

                                                                            
                                                                            
                      PROPHASE LABS, INC. & SUBSIDARIES                     
                    CONSOLIDATED STATEMENTS OF OPERATIONS                   
                  (in thousands, except per share amounts)                  
                                 (unaudited)                                
                                                                            
                              Three Months Ended          Year Ended        
                                  December 31,            December 31,      
                            ----------------------- ----------------------- 
                                2011        2010        2011        2010    
                            ----------- ----------- ----------- ----------- 
                                                                            
Net sales                   $     7,460 $     6,191 $    17,453 $    14,502 
                                                                            
Cost of sales                     2,664       2,612       6,171       5,672 
                            ----------- ----------- ----------- ----------- 
                                                                            
Gross profit                      4,796       3,579      11,282       8,830 
                            ----------- ----------- ----------- ----------- 
                                                                            
Operating expenses:                                                         
  Sales and marketing             4,528       3,158       7,904       5,576 
  Administrative                  1,607       1,523       5,028       6,054 
  Research and development          494          82       1,088         794 
                            ----------- ----------- ----------- ----------- 
  Total operating expense         6,629       4,763      14,020      12,424 
                            ----------- ----------- ----------- ----------- 
                                                                            
Loss from operations             (1,833)     (1,184)     (2,738)     (3,594)
                                                                            
Interest income                       2          12          28          53 
                            ----------- ----------- ----------- ----------- 
                                                                            
Loss from operations before                                                 
 taxes                           (1,831)     (1,172)     (2,710)     (3,541)
                                                                            
Income tax (benefit)                  -         (40)          -         (40)
                            ----------- ----------- ----------- ----------- 
                                                                            
Net loss                    $    (1,831)$    (1,132)$    (2,710)$    (3,501)
                            =========== =========== =========== =========== 
                                                                            
Basic and dilutive loss per                                                 
 share                      $     (0.12)$     (0.08)$     (0.18)$     (0.25)
                            =========== =========== =========== =========== 
                                                                            
Weighted average common                                                     
 shares outstanding:                                                        
  Basic and diluted              14,609      14,684      14,817      14,285 
                            =========== =========== =========== =========== 
                                                                            
                                                                            
                                                         
                                                         
           ProPhase Labs, Inc. and Subsidiaries          
        Condensed Consolidated Balance Sheet Data        
                      (in thousands)                     
                       (unaudited)                       
                                                         
                               December 31,  December 31,
                                   2011          2010    
                               ------------  ------------
                                                         
Cash and cash equivalents      $      5,541  $      8,232
Accounts receivable, net       $      3,219  $      4,821
Inventory                      $      2,688  $      1,682
Total current assets           $     13,195  $     15,756
Total assets                   $     19,079  $     21,695
                                                         
Total current liabilities      $      7,853  $      8,235
Total stockholders' equity     $     11,226  $     13,460
                                                         
                                                         

Contact info:

Press Only Contact
Jenny Miranda
5W Public Relations
Tel: (212) 584-4295
jmiranda@5wpr.com

Investor Contact
Ted Karkus
Chairman and CEO
ProPhase Labs, Inc.
(215) 345-0919 x 0


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->